Pegylated interferon in HBeAg-positive and -negative chronic hepatitis B patients: post-treatment 1-year results of three Turkish centres
Makaleler > Tam Makale · 2013
Yazarlar: Tansu YAMAZHAN, BEHİCE KURTARAN, Hüsnü PULLUKÇU, ESMA Yuksel, Deniz OZKAYA, Meltem TAŞBAKAN, Oğuz Reşat SİPAHİ, İsabel Raika DURUSOY, Hasan Salih Zeki Aksu
Journal of Chemotherapy, SCI Expanded İndekslerine Giren Dergi, Uluslararası, Wos, 2013, cilt 26, ss 339-341
DOI: 10.1179/1973947813y.0000000152
Özet
In this study, we aimed to evaluate the 1-year post-treatment follow-up results of 112 patients who received pegylated interferon (PEG-IFN) for 52 weeks. HBeAg negativity/seroconversion and/or negative HBV-DNA at the end of the treatment were considered as response. Patients who had response at the end of treatment but had HBV-DNA breakthrough during 1-year follow-up were considered as relapse. The study group comprised 112 cases (34 HBeAg-positive, 78 HBeAg-negative). In HBeAg-positive and -negative cases, end-of-treatment response rates were 2·9% and 60·2%, whereas 1-year sustained virological response rates were 0 and 33·3%, respectively. When we compared relapse cases versus cases with response at the end of 1-year follow-up, being female and having low viral load were the two parameters associated with higher response rates (Chi-square, P = 0·028; Mann-Whitney U test, P = 0·023). Overall non-response rates to PEG-IFN were high (57·1%). Results in HBeAg-positive cases were disappointing.